Biomarker based standards and methods of use
AssigneeKite Pharma, Inc.
InventorsHemamali J. Warshakoon, Brandon M. Proctor
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions and methods for fluorescence activated cell analysis of white blood cell populations. The compositions and methods enable thorough characterization each subpopulation of a greater cell population of leukocytes. Additionally, the biomarker-based standards and methods of are expedited as compared to the conventional technology and produce a positive control test material that reduces the cost, expedites the process, and improves the outcome of fluorescence activated cell analysis of blood cell populations.
Claims21
A composition for characterizing a population of cells into subpopulations, comprising:
- a population of biomarker-based standards, wherein each biomarker-based standard comprises:
- a common marker, wherein the common marker corresponds to a marker associated with leukocytes;
- at least one of a plurality of marker sets, wherein the marker sets correspond to marker sets of T cells, NK cells, monocytes, B cells, early progenitor cells, and stem cells;
- and
- a scaffold for restricting relative movement between the common marker and the at least one marker set.
19-27. (canceled)
A kit for characterizing a population of cells into subpopulations, comprising:
- a population of biomarker-based standards, wherein each biomarker-based standards comprises:
- a common marker, wherein the common marker corresponds to a marker associated with leukocytes;
- at least one of a plurality of marker sets, wherein the marker sets correspond to marker sets of T cells, NK cells, monocytes, B cells, early progenitor cells, and stem cells;
- and
- a scaffold for restricting relative movement between the common marker and the at least one marker set;
- and
- an antibody cocktail.
A method for characterizing a population of cells into subpopulations, the method comprising:
- providing a biological sample comprising a population of leukocytes, wherein the population of leukocytes comprises a plurality of subpopulations, wherein the subpopulations comprise T cells, NK cells, monocytes, B cells, B progenitor cells, and stem cells;
- providing a known quantity of a population of biomarker-based standards, wherein the biomarker-based standards comprise:
- a common marker, wherein the common marker corresponds to a marker associated with leukocytes;
- at least one of a plurality of marker sets, wherein the marker sets correspond to marker sets of T cells, NK cells, monocytes, B cells, early progenitor cells, and stem cells;
- and
- a scaffold for restricting relative movement between the common marker and the at least one marker set;
- contacting the population of leukocytes and the population of biomarker-based standards with an antibody cocktail to create a mixture;
- analyzing the mixture with an analytical device;
- and
- characterizing the population of cells by subpopulation using the biomarker-based standards as a reference.
Dependencies are inferred from the claim text.